DSGN SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 28, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Design Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Updates

Nov 4, 2026

8-K

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

Aug 3, 2026

8-K

Design Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 11, 2026

8-K

Design Therapeutics Announces Positive Phase 1/2 Clinical and Biomarker Data for DT-216P2 in Friedreich Ataxia

May 18, 2026

8-K

Design Therapeutics Reports Q1 2026 Financial Results and Pipeline Updates

Apr 28, 2026

8-K

Design Therapeutics, Inc. Appoints David Shapiro, M.D. to Board of Directors

Apr 1, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* November 2026 ATM | Offering amount: $200,000,000 | Bank: Jefferies LLC

Nov 4, 2026

424B4

12,000,000 Shares-

Mar 26, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-3

November 2026 SHELF

Nov 4, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 9, 2026

S-3

May 2025 SHELF & ATM

May 7, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 10, 2025

S-8

Registration

Mar 19, 2024

S-8

Registration

Mar 14, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2026

DEFR14A

Form DEFR14A - Revised definitive proxy soliciting materials

Apr 30, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2024

Ownerships

TYPE

HEADLINE

FILED AT

S-3

Form S-3 - Registration statement under Securities Act of 1933

Nov 4, 2026

SCHEDULE 13G/A

Point72 Asset Management, L.P. (Filed by)

Aug 14, 2026

SCHEDULE 13G

Sirenia Capital Management LP (Filed by)

Aug 14, 2026

George Simeon (Reporting)

Jun 11, 2026

Schmid John P. (Reporting)

Jun 11, 2026

LAPPE RODNEY W (Reporting)

Jun 11, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 19, 2025

CORRESP

Form CORRESP - Correspondence

May 14, 2025

LETTER

Form UPLOAD - SEC-generated letter

May 13, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

May 10, 2022

CORRESP

Form CORRESP - Correspondence

May 5, 2022

CORRESP

Form CORRESP - Correspondence

May 2, 2022

Design Therapeutics, Inc. DSGN · SEC Filings